Detalle Publicación

ARTÍCULO
Radio-223 en el tratamiento de metástasis óseas en pacientes con cáncer de próstata resistente a la castración. Revisión de la literatura y procedimiento
Autores: Orcajo-Rincon, J.; Caresia-Arortegui, A. P. (Autor de correspondencia); Cozar-Santiago, M. D. ; Garcia-Garzon, J. R. ; de Arcocha-Torres, M.; Delgado-Bolton, R. C.; García Velloso, María José; Alvarez-Ruiz, S.; Garcia-Vicente, A. M.
Título de la revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
ISSN: 2253-654X
Volumen: 37
Número: 5
Páginas: 330 - 337
Fecha de publicación: 2018
Lugar: WOS
Resumen:
Bone metastatic disease is the main cause of morbidity / mortality in patients with prostate cancer, presenting frequently as bone pain, pathological fractures or spinal cord compression, which requires early and timely therapy. Although, for the moment, the therapeutic window for its use has not been definitively established, radium-223 (Ra-223), an alpha particle emitter, has proved to be an effective therapeutic tool, pre or post-chemotherapy, in patients with castration-resistant prostate cancer with symptomatic bone metastases and absence of visceral metastases, significantly modifying the prognosis of the disease. It is therefore imperative to define the ideal scenarios and the correct protocol for the use of this therapy and thus offer the greatest possible clinical benefit to the patient. (C) 2018 Sociedad Espanola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espana, S.L.U. All rights reserved.